Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityActive in the last 2 years

Jianxin Lyu

Matched on ORCID iD 0000-0003-2343-1666; OpenAlex author ID A5091548233. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 8

  1. Nutrient stress-induced FTH1 safeguards redox balance and fuels pancreatic ductal adenocarcinoma growth while serving as a therapeutic target and diagnostic bi… Co-author DOI 10.1007/s13402-026-01237-y↗
  2. Dynamic Alterations of Site-Specific N-Glycoform and Plasma Proteasome Signatures Stratify Chemotherapy Benefit in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.mcpro.2026.101642↗
  3. 7-Dehydrocholesterol-mediated ferroptosis is governed by glucose availability in pancreatic ductal adenocarcinoma. Co-author DOI 10.3724/abbs.2026106↗
  4. β-hydroxybutyrate dehydrogenase promotes pancreatic cancer cell proliferation through regulation of the NAD+/NADH balance and mitochondrial acetylation. Last author DOI 10.1016/j.jbc.2025.110636↗
  5. The integral membrane protein smim4 modulates redox balance via malate compartmentalization in pancreatic cancer. Co-author DOI 10.1038/s41467-025-64734-y↗
  6. Activated Natural Killer Cells-Dependent Dendritic Cells Recruitment and Maturation by Responsive Nanogels for Targeting Pancreatic Cancer Immunotherapy. Co-author DOI 10.1002/smll.202203114↗
  7. 4-Hydroxyphenylpyruvate Dioxygenase-Like Protein Promotes Pancreatic Cancer Cell Progression and Is Associated With Glutamine-Mediated Redox Balance. Co-author DOI 10.3389/fonc.2020.617190↗
  8. Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth. Last author DOI 10.1038/s41419-017-0196-z↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hezhi Fang · 6 shared papers, 2018–2026 · strength 1.16
  2. Xiujuan Wei · 3 shared papers, 2020–2026 · strength 0.60
  3. Wei Cui · 2 shared papers, 2025–2026 · strength 0.47
  4. Minghua Jiang · 1 shared paper, 2026 · strength 0.28
  5. Xiaojun Ren · 1 shared paper, 2026 · strength 0.28
  6. Shanying Gui · 1 shared paper, 2026 · strength 0.27
  7. Wenhui Ouyang · 1 shared paper, 2026 · strength 0.27
  8. Xiaojun Ren · 1 shared paper, 2026 · strength 0.26
  9. Ziwei Zhang · 1 shared paper, 2026 · strength 0.26
  10. Bo Wang · 1 shared paper, 2025 · strength 0.20
  11. Minghua Jiang · 1 shared paper, 2025 · strength 0.20
  12. Hongwei Sun · 2 shared papers, 2018–2020 · strength 0.17
  13. Jilong Wang · 1 shared paper, 2022 · strength 0.16
  14. Junjie Deng · 1 shared paper, 2022 · strength 0.16
  15. Zhen Wang · 1 shared paper, 2022 · strength 0.16
  16. Xianglai Ye · 1 shared paper, 2020 · strength 0.10
  17. Xujun He · 1 shared paper, 2020 · strength 0.10
  18. Chao Hui ZHOU · 1 shared paper, 2018 · strength 0.07
  19. Jing Gao · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.